Novelty Nobility, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Apollo Licenses Ex-China Rights T

As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as othe

South Korean bioventures have experienced a harsh financing environment in 2023 stemming from economic depression, high interest rates and a general deterioration in investor sentiment. Although most

While the global biopharma industry saw lackluster deal-making activity in 2022, transactions involving antibody-drug conjugates (ADCs) continued to rise amid the global commercial success of Daiichi